Original Article

Various phenotypes of short stature with heterozygous IGF-1 receptor (IGF1R) mutations

Yuki Kawashima-Sonoyama¹,⁶, Tomoyuki Hotsubo², Takashi Hamajima³, Naoki Hamajima⁴, Masanobu Fujimoto¹, Noriyuki Namba¹, and Susumu Kanzaki¹,⁵

¹ Division of Pediatrics & Perinatology, Tottori University Faculty of Medicine, Yonago, Japan
² Sapporo Children’s Endocrine Clinic, Sapporo, Japan
³ Department of Pediatric Endocrinology and Metabolism, Aichi Children’s Health and Medical Center, Obu, Japan
⁴ Department of Pediatrics, Nagoya City West Medical Center, Nagoya, Japan
⁵ Asahigawaso Rehabilitation and Medical Center, Okayama, Japan.
⁶ Department of Pediatrics, Shimane University Faculty of Medicine, Izumo, Japan

Phenotypic features of IGF1R mutation

Corresponding Author

Yuki Kawashima-Sonoyama

Department of Pediatrics, Shimane University Faculty of Medicine
89-1, En-ya-cho, Izumo, Shimane, 693-8501, Japan
Tel: +81-853-20-2218, Fax: +81-853-20-2215
E-mail: yuki.kawashima@med.shimane-u.ac.jp
Abstract

Type 1 insulin-like growth factor receptor (IGF1R) plays an important role in normal fetal and postnatal growth. Over 30 pathogenic variants of IGF1R have been identified in patients with short stature. Yet, 20 years after the first report, a variety of phenotypes remain poorly defined. We analyzed the genetic and clinical data and responses to growth hormone (GH) therapy in 11 patients using results from questionnaires. Eight of the 11 patients have already been reported in previous articles, and all of the identified mutations were heterozygous. The patients exhibited various phenotypes. At least two patients did not meet the criteria for GH treatment for small for gestational age (SGA) short stature, and two more patients showed lower serum IGF1 levels. Nine of the 11 patients had thin upper lips. Five patients with heterozygous IGF1R treated with GH exhibited similar height gains to those reported in previous Japanese studies on SGA short stature, which also led to extremely high serum IGF1 levels. Patients with short stature due to IGF1R mutations exhibit various phenotypes. Their presentation at diagnosis may be indistinguishable from common short stature. More specific clinical scoring that considers elevated IGF1 levels after GH treatment is needed to better detect IGF1R mutations.

Highlights:

- Patients with heterozygous IGF1R mutations have heterogeneous phenotypes
- Recombinant GH therapy might be effective in treating IGF1R-related short stature
- Higher IGF1 levels after rhGH treatment may indicate IGF1R gene mutations

Key words: Insulin-like growth factor 1 receptor (IGF1R), short stature, growth hormone therapy, insulin-like growth factor 1 (IGF1)
Introduction

Type 1 insulin-like growth factor receptor (IGF1R) is widely expressed in many cell types in fetal and postnatal tissues. IGF1R is activated by the secreted growth factor ligands IGF1 and IGF2, which elicit cellular responses to promote fetal somatic growth. This postnatal somatic growth is achieved through synergistic interactions between growth hormone (GH) and IGFS (1, 2). IGF1R is important for normal fetal and postnatal growth and development (3, 4).

Almost 20 years after the first cases with IGF1R mutations were reported, over 30 pathogenic mutations and defects of IGF1R have been identified as contributing to short stature (5-17). Walenkamp et al. reported the detection of pathogenic IGF1R mutations in approximately 2% of patients with short stature who were small for gestational age (SGA) (18). Most cases had heterozygous IGF1R mutations or haploinsufficiency, although several compound heterozygous and two homozygous mutations of IGF1R have been reported (19). As IGF1R-null mice die soon after birth due to respiratory failure, the total loss of IGF1R function in mammals is considered lethal (4). Reported cases of heterozygous IGF1R mutation or haploinsufficiency show persistent postnatal and intrauterine growth retardation with elevated serum IGF1 and microcephaly (9-12, 14). Other reported phenotypic features include mildly impaired glucose tolerance, motor and mental retardation, and mild dysmorphic features, including clinodactyly, triangular face, hypotelorism, low-set ears, thin upper lip, and high-arched palate (5, 8, 14, 15, 20). However, there are a variety of phenotypes, and the degree of growth retardation is highly variable. For instance, Klammt et al. reported that eight patients with an IGF1R mutation had a birth weight (BW) ranging from -1.5 to -3.5 standard deviation score (SDS), birth length (BL) varying from -0.3 to -5.0 SDS, and last reported height ranging from -2.1 to -5.0 SDS (21). The phenotypes of IGF1R mutations and defects remain poorly defined, and the variability in phenotype makes it
difficult for physicians to identify patients who should be tested for *IGF1R* defects. To date, no studies on the growth profile and phenotypes in case series with heterozygous *IGF1R* mutations or haploinsufficiency have been conducted in Japan.

Recently, two studies revealed the growth profile phenotype and recombinant human growth hormone (rhGH) therapy response in patients with heterozygous *IGF1R* mutations and defects (18, 22). Here, we present the first study of the phenotype, growth profile, and rhGH therapy response in patients with short stature and heterozygous *IGF1R* mutations in Japan.

**Materials and Methods**

*Questionnaire and data analysis*

Between December 2020 and March 2021, we recruited and provided a questionnaire to doctors attending to previously reported patients with *IGF1R* mutations who were identified by our comprehensive genetic testing study for unexplained growth disorders. The questionnaire asked about patient age, sex, BW, birth height (BH), head circumference (HC), peak serum GH level in the GH provocation test, serum IGF1 level, height (including final height), bone age, hemoglobin A1c (HbA1c; before, during, and after rhGH treatment), complications, and patient genotype. We carefully analyzed 11 patients based on the results of the questionnaire. The SDS values for BW, BH, HC, and height were calculated based on Japanese data regarding standard height by sex and age (23, 24). The IGF1 SDS was calculated using Japanese reference values of serum IGF1 concentrations in children by sex and age (25). Statistical analyses were performed using Microsoft® Excel® 2019 to compare groups using *t*-test and two-way ANOVA followed by Dunnel’s test. The results are shown as mean ± SD. Statistical significance was set at *p* < 0.05.
**Sequence analysis of IGF1R**

Genomic DNA was isolated from peripheral blood lymphocytes of the patients. PCR and direct sequencing of the PCR products were performed as previously described (13). Targeted resequencing was performed on patients 9–11, using TruSight One sequencing panels (Illumina, San Diego, CA, USA), which included 4,813 genes associated with known clinical phenotypes, as previously described (26). We analyzed genes (including GH, GHR, STAT5, STAT3, IGF1R, IGF1, IGF2, IGFBP3, IGFALS, IRS1, IRS2, ACAN, COL2A1, COL11A1, FLNB, and FGFR3) associated with GH-IGF signals and growth plates, as well as other causative genes associated with short stature (IHH, SHOX, PTPN11, NF1, and NPR2) in the panel. Variant filtering was performed using SnpEff and SnpSift software, which collects variant-specific information by allelic frequency in all patients, and in the HGVD, GWAS, and dbSNP variant databases, as previously described (26).

**In silico analysis**

All variants and mutations detected in the sequence analysis described above were analyzed using three prediction algorithms (Mutation Taster, PolyPhen-2, and CADD) to calculate the prediction scores of pathogenicity in the in silico analysis.

**Ethical approval**

The Ethical Review Board of Tottori University Faculty of Medicine approved this study (questionnaire and data analysis approval: 20A068; sequence analysis approval: G173). The study was performed in accordance with the principles set out in the Declaration of Helsinki.

**Results**

**Identified heterozygous IGF1R mutations**

We analyzed data from 11 patients with heterozygous IGF1R mutations (Table 1,
Figure 1). Eight of the 11 patients have been previously reported (7, 13, 27, 28). All of the identified mutations were heterozygous. Table 1 shows the order of patients. The p.Arg739Gln mutation (Family A) resulted in a change in the cleavage site from Arg-Lys-Arg-Arg to Arg-Lys-Gln-Arg, which led to the failure of IGF1R proreceptor processing (13). The dominant negative effects of these mutations have not been evaluated. The p.Arg461Leu mutation (Family B) is located in the L2 domain of the IGF1R α chain, leading to a decrease in the internalization of IGF1R (7). p.Asp1135Glu (Family C) leads to a defect in tyrosine phosphorylation of IGF1R and has a dominant negative effect on IGF1R [28]. p.Gln1250* (Family D), p.Trp1249* (Family E), and p.Tyr888* (Family F) are nonsense mutations that lead to decreased or absent IGF1R protein expression, as confirmed using R² cells transiently transfected with p.Tyr888* IGF1R (unpublished data). These findings resemble IGF1R haploinsufficiency (27). Family F entered our comprehensive genetic testing study for an unexplained growth disorder. With ethical approval (G173), the family underwent targeted resequencing using TruSight One sequencing panels. No alterations in any other potentially causative genes of short stature were detected in this family. We also analyzed the mutations using PolyPhen, Mutation Taster, and CADD scores. Based on previous functional analysis and in silico analyses, p.Arg461Leu was considered the mildest type. Although the CADD score for p.Asp1135Glu is lower than that for nonsense mutations (p.Gln1250*, p.Trp1249*, and p.Tyr888*), the p.Asp1135Glu mutation is considered the most severe missense mutation because of its dominant negative effect.

**Phenotypic features**

As shown in Table 2, almost all patients presented with short stature (below -2 SDS), while the mother in Family B and the father in Family F did not present with short stature. The Family B-mother harbored a p.Arg461Leu mutation, which led to decreased cell
proliferation and decreased internalization of IGF1R, but with unaffected IGF1 signaling and cell proliferation (7). Furthermore, her CADD score was the lowest, and the prediction of amino acid substitution by Poly Phen was “benign.” These findings suggest that the p.Arg461Leu mutation is the mildest form in our study.

The Family F-father harbored the p.Tyr888* nonsense mutation. His final height was -1.93 SDS. He has a lower BW (-1.82 SDS). Data for his BH and HC were not available. Patients harboring mutations with higher CADD scores or dominant negative effects (p.Asp1135Glu) had relatively shorter statures than patients with other mutations. Patients with pathogenic IGF1R mutations are usually born with low BW. In the present study, all patients presented with a BW SDS below -1.26, but they did not always present SGA (<-10% tile [1.33 SDS]). Furthermore, BW and BH for the Family A-proband and Family F-sister did not meet the criteria for GH treatment for SGA short stature (both BW and BL were below -10% percentile; BW or BL must be below -2SD), and were not able to receive GH treatment despite their short stature. Although the Family F-mother did not have the mutation, the proband, sister, and father in Family F harbored the same nonsense mutation (p.Tyr888*). However, they exhibited different phenotypes. The Family F-proband had SGA short stature, Family F-sister had short stature without SGA, and Family F-father was born SGA, but attained a normal height. These individuals did not show any other symptoms except growth problems. Surprisingly, serum IGF1 levels before rhGH treatment were not elevated in all patients (-0.56-3.44 SDS), and the proband and sister in Family F had lower serum IGF1 levels (-0.45, -0.56, respectively). Some patients (Family B-proband, Family C-proband, Family E-proband) showed elevated GH peak levels in the GH provocation test. All patients (Family A-proband, Family B-proband, Family C-proband Family D-proband, Family E-proband, Family F-proband and sister) with relevant data showed bone age delay (chronological age: bone age; mean 1.68±0.81, data not shown). Two of the patients had complications. Family A-proband displayed mental retardation (IQ score: 60). Family C-
mother, who had the p.Asp1135Glu mutation, had type 2 diabetes. Although we could not evaluate whether the p.Asp1135Glu mutation has a dominant effect on the insulin receptor (unpublished data), the mutation might also have an effect on the insulin receptor. Although all patients had no clinodactyly, triangular face, hypotelorism, or a high-arched palate, nine of 11 patients had thin upper lips.

In summary, patients with heterozygous IGF1R mutations exhibited various phenotypes. The genotype may affect the phenotype, but not all patients exhibited short stature, had elevated serum IGF1 levels, or were born SGA.

rhGH therapy for patients with heterozygous IGF1R mutation

To date, many patients with IGF1R gene mutations have been administered rhGH treatment without side effects (5, 6, 9, 15, 17, 18, 22, 29). In this study, five patients (Family B-proband, Family C-proband, Family D-proband, Family E-proband, Family F-proband) received rhGH therapy for SGA-related short stature (Table 3, Figure 2). Two patients (Family B-proband, and Family C-proband) completed rhGH therapy because of epiphyseal closure. Therapy was stopped for one patient (Family D-proband) at the patient’s request before epiphyseal closure. The patient’s growth rate had decreased as the physician had reduced the rhGH dose to 0.2 mg·kg⁻¹·week⁻¹ due to a markedly high IGF1 level. The patient did not show any other side effects, except an elevated serum IGF1 level. Family E-proband and Family F-proband continued rhGH treatment. All patients started GH therapy with low doses of rhGH (0.23–0.25 mg·kg⁻¹·week⁻¹). Family C-proband and F-proband received higher doses of rhGH (0.31–0.35 mg·kg⁻¹·week⁻¹) 1 yr after the start of therapy. Family C-proband also received an increased dose of rhGH (0.45 mg·kg⁻¹·week⁻¹) 2 yr after the start of therapy. Family B-proband received rhGH as a trial for low-dose rhGH treatment for SGA short stature for 3 yr. She restarted rhGH treatment at 10 years of age and was treated with a
gonadotropin-releasing hormone analog from 10 to 12.4 yr of age. We only used data from rhGH treatment (Table 3 and Figure 2A and B). None of the patients experienced any obvious complications. The mean height ΔSDS for chronological age 1 yr after the initiation of rhGH treatment was 0.62±0.278 SDS, which is similar to the effect reported in Japanese studies of rhGH therapy for SGA short stature (0.63±0.32 SDS (30). The other annual height ΔSDS we observed was also similar to previous reports on SGA-related short stature in Japan (30-32).

The rhGH treatment to the heterozygous IGF1R mutation (Family C-proband, Family D-proband, Family E-proband) for 5 yr resulted in similar height gain (-3.03±0.04−1.64±0.57 SDS) compared with previous Japanese studies on rhGH therapy for SGA-related short stature (-3.02±0.65−1.23±0.91 SDS) (32). There was a significant difference (p<0.05) between the heights 2–5 yr after rhGH treatment and the height before rhGH treatment. Interestingly, in Family C, the proband (p.As1135 Glu) had a normal final height (-1.61 SD) after rhGH treatment, while the Family mother, who had not received GH treatment, had severely short stature (-3.98 SD) (Figure 2D, Figure 3). Figure 2C shows the Δ height SDS with rhGH treatment (start to the final height). The Family D-proband, though had stopped rhGH therapy before epiphyseal closure. Height gain with rhGH treatment had been poor. The other two patients (probands in Family B and C) showed increased height gain with rhGH treatment (Figure 3). These results, as well as those shown in Figure 2A, 2D, and Figure 3, suggest that rhGH therapy for patients with the heterozygous IGF1R mutation can be considered somewhat effective, which is consistent with previous studies (18, 29).

Furthermore, the mean serum IGF1 level after rhGH treatment was significantly increased (Table 3, Figure 2B). Although mean serum IGF1 at baseline was within the normal range (-1.23±1.05 SDS), mean serum IGF1 SDS 1 yr after rhGH treatment exceeded 3 SDS (3.84±1.29 SDS), increased to over 5.0 SDS (5.0±1.27 SDS) after 2 yr of treatment, and reached 6.1 SDS (6.1 ±0.34 SDS). There was no significant increase between from 2–5 yr after the treatment. Since Horikawa et al. (32) reported that the mean serum IGF1 SDS 1 and
5 yr after GH treatment of SGA short stature was 0.10 ±1.68 and <0 SD, respectively, the serum IGF1 level after GH treatment in patients with the heterozygous IGF1R mutation can be considered to have been extremely elevated in our study. There was a significant difference (p<0.05) in serum IGF1 levels 5 yr after rhGH treatment and serum IGF1 levels before rhGH treatment.

Discussion

The phenotype of short stature with IGF1R mutations remains poorly understood, and there is no approved therapy for short stature with IGF1R mutations, although a previous study reported the efficacy of GH treatment (5, 6, 9, 15, 17, 18, 22, 29). In this study, we report the genetic, clinical, and biochemical data of 11 patients with heterozygous IGF1R mutations. Five of the patients had heterozygous nonsense mutations. The other six had heterozygous missense mutations. The various phenotypes of heterozygous IGF1R mutations were determined. The data revealed that rhGH therapy in patients with heterozygous IGF1R mutations led to extreme increases in serum IGF1 levels, resulting in height gain without complications.

The classical and typical phenotypes of short stature with pathogenic IGF1R mutations and defects are SGA birth, elevated serum IGF1 levels, and GH peak values in the provocation test (9-12, 14). However, recent studies have revealed that some patients have a mild phenotype (normal stature, normal BW and BL, non-elevated serum IGF1 levels) (18, 21), which is consistent with our study. Surprisingly, Family A-proband was not born with SGA. Her height was approximately -2 SD, although her final height became more severely negatively impacted (-2.3 SD). The serum IGF1 for the proband and sister in Family F was <0 SD. Normally, IGF1 is controlled by GH and IGF1R, and by nutrition and insulin. Furthermore, most of the serum IGF1 is composed of ternary complexes with IGFBP3 or
IGFBP5 and IGFALS. This means that the serum IGF1 level does not accurately reflect the insensitivity of IGF1. The proband and sister in Family F did not have any major nutritional problems. Mild malnutrition might be hidden. However, the actual cause of low serum IGF1 levels is unknown. Furthermore, IGF1R is expressed in almost all tissues and cells, and there are tissue-specific differences in its distribution. This variability in the phenotype of Family F might correlate with the differential distribution of mutated IGF1R. Further studies are required to clarify this.

This phenotypic variability leads to the important issue of which patients should be tested for IGF1R mutations. Walenkamp et al. (18) determined the clinical score for molecular defects of IGF1R as follows: BW and/or BL, < -1 SDS; height SDS at presentation: < -2.5 SDS, HC at presentation: < -2 SDS, IGF1: >0 SDS. A score of >3 had 87% specificity (18). Scores >3 had 55% sensitivity in our study. This lower sensitivity in our study might be related to the lack of information on HC at birth. However, the Family F-proband and sister, who had normal birth HC, had a score of 2 which means that the clinical score by Walenkamp et al. is insufficient for the diagnosis. Since both our study and previous studies reported higher serum IGF levels after GH treatment, and 9 of 11 patients had thin upper lips, the extremely higher serum IGF levels after GH treatment and thin upper lip may also be added to the clinical score. These findings highlight the need for a more specific clinical score for the detection of IGF1R mutations.

There are cases with IGF1R mutations that showed less response to GH treatment compared with most other SGA patients, and this lower response to GH is considered to be associated with IGF1 resistance. Some older reports classified SGA patients with GH resistance as having IGF1R gene anomalies (33, 34). However, patients with IGF1R mutations and defects have received GH treatment in many studies (5, 6, 9, 15, 17, 18, 22, 29), with all patients achieving moderately effective height gains without side effects. Furthermore, Göpel et al. (22) reported that some patients with IGF1R mutations respond
poorly to therapy, while others are good responders, for reasons still unknown. Although our sample size was small, we observed a similar height gain compared with previous reports on Japanese patients undergoing rhGH therapy for SGA-related short stature (30-32). The present and previous findings suggest that rhGH therapy may be a first-line approach for short stature resulting from IGF1R mutations. There is no approved therapy for short stature due to IGF1R mutations or defects in Japan. Since patients with IGF1R mutations and defects without SGA cannot receive rhGH treatment in Japan (e.g., Family F-sister), an approved treatment for short stature due to IGF1R mutations is needed. rhGH treatment is a candidate option.

This study has several limitations. The sample size was small. Only five patients received rhGH therapy for SGA-related short stature. Of these, only three patients had reached their final height. One of these three patients (Family D-proband) stopped rhGH therapy because of elevated IGF1 levels before epiphyseal closure. Moreover, two of five patients (probands in Family E and F) were receiving ongoing rhGH treatment. The sample size was be greater to conclusively assess the efficacy of rhGH therapy for short stature due to IGF1R mutations.

This study provides the first data of the phenotype, growth profile, and rhGH therapy response in Japanese individuals with short stature and heterozygous IGF1R mutations. There are various phenotypes of heterozygous IGF1R mutations, including extremely high serum IGF1 levels, resulting in height gain without complications after rhGH therapy. Higher serum IGF1 levels after GH treatment are considered an important sign of IGF1R gene mutations. Since short stature due to IGF1R mutations has various phenotypes, and because diagnosis may be difficult, we need a more specific clinical score for the detection of IGF1R mutations.
Disclosure

None of the authors have any potential conflicts of interest associated with this research.
1. Baserga R. The IGF-I receptor in cancer research. Exp Cell Res 1999;253:1-6.
2. LeRoith D, Roberts CT. The insulin-like growth factor system and cancer. Cancer Lett 2003;195:127-137.
3. Baker J, Liu JP, Robertson EJ, Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993;75:73-82.
4. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (igf-1) and type 1 IGF receptor (Igf1r). Cell 1993;75:59-72.
5. Veenma DC, Eussen HJ, Govaerts LC, de Kort SW, Odink RJ, et al. Phenotype-genotype correlation in a familial IGF1R microdeletion case. J Med Genet 2010;47:492-498.
6. Kawashima Y, Takahashi S, Kanzaki S. Familial short stature with IGF-I receptor gene anomaly. Endocr J 2012;59:179-185.
7. Kawashima Y, Higaki K, Fukushima T, Hakuno F, Nagaishi J, Hanaki K, et al. Novel missense mutation in the IGF-I receptor L2 domain results in intrauterine and postnatal growth retardation. Clin Endocrinol (Oxf) 2012;77:246-254.
8. Choi JH, Kang M, Kim GH, Hong M, Jin HY, Lee BH, et al. Clinical and functional characteristics of a novel heterozygous mutation of the IGF1R gene and IGF1R haploinsufficiency due to terminal 15q26.2-pter deletion in patients with intrauterine growth retardation and postnatal catch-up growth failure. J Clin Endocrinol Metab 2012;96:E130-4.
9. Wallborn T, Wuller S, Klammt J, Kruis T, Kratzsch J, Schmidt G, et al. A heterozygous mutation of the insulin-like growth factor-I receptor causes retention of the nascent protein in the endoplasmic reticulum and results in intrauterine and postnatal growth retardation. J Clin Endocrinol Metab 2010;95:2316-2324.
10. Kruis T, Klammt J, Galli-Tsinopoulou A, Wallborn T, Schlicke M, Müller E, et al. Heterozygous mutation within a kinase-conserved motif of the insulin-like growth factor I
receptor causes intrauterine and postnatal growth retardation. *J Clin Endocrinol Metab* 2010;95:1137-1142.

11. Walenkamp MJ, van der Kamp HJ, Pereira AM, Kant SG, van Duyvenvoorde HA, Kruithof MF, *et al.* A variable degree of intrauterine and postnatal growth retardation in a family with a missense mutation in the insulin-like growth factor I receptor. *J Clin Endocrinol Metab* 2006;91:3062-3070.

12. Raile K, Klammt J, Schneider A, Keller A, Laue S, Smith R, *et al.* Clinical and functional characteristics of the human Arg59Ter insulin-like growth factor I receptor (IGF1R) mutation: Implications for a gene dosage effect of the human IGF1R. *J Clin Endocrinol Metab* 2006;91:2264-2271.

13. Kawashima Y, Kanzaki S, Yang F, Kinoshita T, Hanaki K, Nagaishi JI, *et al.* Mutation at cleavage site of insulin-like growth factor receptor in a short-stature child born with intrauterine growth retardation. *J Clin Endocrinol Metab* 2005;90:4679-4687.

14. Abuzzahab MJ, Schneider A, Goddard A, Grigorescu F, Lautier C, Keller E, *et al.* IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. *N Engl J Med* 2003;349:2211-2222.

15. Okubo Y, Siddle K, Firth H, O'Rahilly S, Wilson LC, Willatt L, *et al.* Cell proliferation activities on skin fibroblasts from a short child with absence of one copy of the type 1 insulin-like growth factor receptor (IGF1R) gene and a tall child with three copies of the IGF1R gene. *J Clin Endocrinol Metab* 2003;88:5981-5988.

16. Ester WA, van Duyvenvoorde HA, de Wit CC, Broekman AJ, Ruivenkamp CA, Govaerts LC *et al.* Two short children born small for gestational age with insulin-like growth factor 1 receptor haploinsufficiency illustrate the heterogeneity of its phenotype. *J Clin Endocrinol Metab* 2009;94:4717-4727.

17. Fang P, Schwartz ID, Johnson BD, Derr MA, Roberts CT, Hwa V, *et al.* Familial short stature caused by haploinsufficiency of the insulin-like growth factor 1 receptor due to
nonsense-mediated messenger ribonucleic acid decay. *J Clin Endocrinol Metab* 2009;94:1740-1747.

18. Walenkamp MJE, Robers JML, Wit JM, Zandwijken GRJ, van Duyvenvoorde HA, Oostdijk W, *et al.* Phenotypic features and response to GH treatment of patients with a molecular defect of the IGF-1 receptor. *J Clin Endocrinol Metab* 2019;104:3157-3171.

19. Gannage-Yared MH, Klammt J, Chouery E, Corbani S, Megarbane H. Homozygous mutation of the IGF1 receptor gene in a patient with severe pre- and postnatal growth failure and congenital malformations. *Eur J Endocrinol* 2012;168:K1-7.

20. Rujirabanjerd S, Suwannarat W, Srpto T, Dissaneevate P, Permsirivanich W, Limprasert P. De novo subtelomeric deletion of 15q associated with satellite translocation in a child with developmental delay and severe growth retardation. *Am J Med Genet A* 2007;143A: 271-276.

21. Klammt J, Kiess W, Pfaffle R. IGF1R mutations as cause of SGA. *Best Pract Res Clin Endocrinol Metab* 2011;25:191-206.

22. Gopel E, Rockstroh D, Pfaffle H, Schlicke M, Pozza SB, Gannagé-Yared MH *et al.* A comprehensive cohort analysis comparing growth and GH therapy response in IGF1R mutation carriers and SGA children. *J Clin Endocrinol Metab* 2020;105:e1705-171710.1210/clinem/dgz165.

23. Itabashi K, Miura F, Uehara R, Nakamura Y. New Japanese neonatal anthropometric charts for gestational age at birth. *Pediatr Int* 2014;56:702-708.

24. Isojima T, Kato N, Ito Y, Kanzaki S, Murata M Growth standard charts for Japanese children with mean and standard deviation (SD) values based on the year 2000 national survey. *Clin Pediatr Endocrinol* 2016;25:71-76.

25. Isojima T, Shimatsu A, Yokoya S, Chihara K, Tanaka T, Hizuka N, *et al.* Standardized centile curves and reference intervals of serum insulin-like growth factor-I (IGF-I) levels in a normal Japanese population using the LMS method. *Endocr J* 2012;59:771-780.
26. Okazaki T, Murata M, Kai M, Adachi K, Nakagawa N, Kasagi N, et al. Clinical diagnosis of mendelian disorders using a comprehensive gene-targeted panel test for next-generation sequencing. *Yonago Acta Med* 2016;59:118-125.

27. Fujimoto M, Kawashima Sonoyama Y, Hamajima N, Hamajima T, Kumura Y, Miyahara Y, et al. Heterozygous nonsense mutations near the C-terminal region of IGF1R in two patients with small-for-gestational-age-related short stature. *Clin Endocrinol (Oxf)* 2015;83:834-841.

28. Kawashima Y, Hakuno F, Okada S, Hotsubo T, Kinoshita T, Fujimoto M, et al. Familial short stature is associated with a novel dominant-negative heterozygous insulin-like growth factor 1 receptor (IGF1R) mutation. *Clin Endocrinol (Oxf)* 2014;81:312-314.

29. Walenkamp MJ, de Muinck Keizer-Schrama SM, de Mos M, Kalf ME, Van Duyvenvoorde HA, Boot AM, et al. Successful long-term growth hormone therapy in a girl with haploinsufficiency of the insulin-like growth factor-I receptor due to a terminal 15q26.2-qter deletion detected by multiplex ligation probe amplification. *J Clin Endocrinol Metab* 2008;93:2421-2425.

30. Yokoya S, Tanaka T, Itabashi K, Osada H, Hirai H, Seino Y. Efficacy and safety of growth hormone treatment in Japanese children with small-for-gestational-age short stature in accordance with Japanese guidelines. *Clin Pediatr Endocrinol* 2018;27:225-234.

31. Tanaka T, Yokoya S, Hoshino Y, Hiro S, Ohki N. Long-term safety and efficacy of daily recombinant human growth hormone treatment in Japanese short children born small for gestational age: Final report from an open and multi-center study. *Clin Pediatr Endocrinol* 2018;27:145-157.

32. Horikawa R, Tanaka T, Nishinaga H, Nishiba Y, Yokoya S. The long-term safety and effectiveness of growth hormone treatment in japanese children with short stature born small for gestational age. *Clin Pediatr Endocrinol* 2020;29:159-171.
33. Savage MO, Hwa V, David A, Rosenfeld RG, Metherell LA. Genetic defects in the growth hormone-IGF-I axis causing growth hormone insensitivity and impaired linear growth. *Front Endocrinol (Lausanne)* 2011;2:95.

34. David A, Hwa V, Metherell LA, Netchine I, Camacho-Hubner C, Clark AJ, *et al.* Evidence for a continuum of genetic, phenotypic, and biochemical abnormalities in children with growth hormone insensitivity. *Endocr Rev* 2011;32:472-497.
Figure 1 *IGF1R* mutations identified in the present study

Schematic overview of IGF1R mutations in this study. All the mutations were heterozygous.

The amino acid number of IGF1R refers to the IGF1R protein, including the 30 amino acid signal peptide. Abbreviations are: L1, receptor L domain; CR, furin-like cysteine-rich region; L2, receptor L domain; FnIII1, fibronectin type 3 domain; FnIII, type III fibronectin repeats; and TK, tyrosine kinase domain.
Figure 2 Growth profiles and serum IGF1 after rhGH treatment from patients with IGF1R mutations

A: Change in height SDS during 5 yr of GH treatment. *p<0.05 compared with the height before rhGH treatment. B: Change in mean serum IGF1 standard deviation score (SDS) during the 5 yr of GH treatment. *p<0.05. C: The Δ height SDS with rhGH treatment (start to the final height) D: Individual final height for patients with IGF1R mutations with or without rhGH treatment. Data are presented as median ± standard deviation.
Figure 3 Growth curve of Family C-proband

Height and weight were plotted on a cross-sectional growth chart for Japanese girls (0–18 yr) in 2000. Family C-proband was treated with rhGH treatment from 6–14 yr.
| Patients (reference) | Nucleotide change (NM_000875.5) | Amino acid change | Prediction of amino acid substitution (Mutation taster) | Prediction of amino acid substitution (Poly phen) | CADD core (phred) |
|----------------------|----------------------------------|-------------------|-------------------------------------------------------|-------------------------------------------------|------------------|
| Family A-proband (13) | c.2216G>A                        | p.Arg739Gln       | Disease-causing (P value, 0.9999)                      | Probably damaging with a score of 0.980 (sensitivity: 0.75; specificity: 0.96) | 32               |
| Family A-mother (13)  | c.2216G>A                        | p.Arg739Gln       | Disease-causing (P value, 0.9999)                      | Probably damaging with a score of 0.980 (sensitivity: 0.75; specificity: 0.96) | 32               |
| Family B-proband (7)  | c.1382G>T                         | p.Arg461Leu       | Disease-causing (P value, 0.9999)                      | Benign with a score of 0.007 (sensitivity: 0.96; specificity: 0.75)           | 24.3             |
| Family B-mother (7)   | c.1382G>T                         | p.Arg461Leu       | Disease-causing (P value, 0.9999)                      | Benign with a score of 0.007 (sensitivity: 0.96; specificity: 0.75)           | 24.3             |
| Family C-proband (28) | c.3405C>G                         | p.Asp1135Glu      | Disease-causing (P value, 0.9999)                      | probably damaging with a score of 1.000 (sensitivity: 0.00; specificity: 1.00) | 24.2             |
| Family C-mother (28)  | c.3405C>G                         | p.Asp1135Glu      | disease causing (P value,0.9999)                      | probably damaging with a score of 1.000 (sensitivity: 0.00; specificity: 1.00) | 24.2             |
| Family D-proband (27) | c.3748C>T                         | p.Gln1250*        | Disease causing (P value,1)                           |                                                  | 51               |
| Family E-proband (27) | c.3746C>T                         | p.Trp1249*        | Disease-causing (P value, 0.9999)                      |                                                  | 54               |
| Family F-proband (-)  | c.2664T>A                         | p.Tyr888*         | Disease-causing (P value, 1)                          |                                                  | 33               |
| Family F-sister (-)   | c.2664T>A                         | p.Tyr888*         | Disease-causing (P value, 1)                          |                                                  | 33               |
| Family F-father (-)   | c.2664T>A                         | p.Tyr888*         | Disease-causing (P value, 1)                          |                                                  | 33               |
| Patients (reference) | Amino acid change | Sex | Age | BW (SD) | BH (SD) | HC (SD) | Height (duration of GH therapy) | GH therapy (duration of GH therapy) | Serum IGF-1 (µg/L) | GH peak value (L-DOPA) | Mild dysmorphic features | Complication | GnRH therapy (duration) |
|---------------------|------------------|-----|-----|---------|---------|---------|-------------------------------|----------------------------------|-------------------|---------------------|-----------------------------|--------------|------------------------|
| Family A-proband (13) | p.Arg739Gln | F | 24 | -1.26 | -0.78 | NO | -2.30 | 1.41 | Thin upper lip | Mental retardation | NO | |
| Family A-mother (13) | p.Arg739Gln | F | 53 | -2.29 | -3.43 | Yes | -2.85 | 1.81 | Thin upper lip | NO | |
| Family B-proband (7) | p.Arg461Leu | F | 20 | -1.66 | -2.77 | Yes | -1.81 | 0.09 | 37.4 (L-DOPA) | Thin upper lip | Yes (2 yr: 10.4 yr old→12.4 y) | |
| Family B-mother (7) | p.Arg461Leu | F | 46 | -1.55 | -0.24 | No | -1.15 | Thin upper lip | NO | |
| Family C-proband (28) | p.Asp1135Glu | F | 18 | -1.3 | -2.16 | Yes | -1.61 | 3.22 | 35.2 (Arginine) | Thin upper lip | Yes (4 mo: 12.3 yr) | |
| Family C-mother (28) | p.Asp1135Glu | F | 53 | -2.23 | -2.36 | No | -3.98 | Thin upper lip | Type 2 Diabetes | NO | |
| Family D-proband (27) | p.Gln1250* | M | 18 | -3.37 | -2.08 | -3.7 | -3.09 | Yes | 3.60 | 15.6 (Arginine) | NO | |
| Family E-proband (27) | p.Trp1249* | F | 10 | -3.01 | -2.83 | -2.63 | -3 | Yes | 0.36 | 28.32 (Clonidine) | NO | |
| Family F-proband (-) | p.Tyr888* | M | 5 | -2.49 | -2.67 | -1.66 | -3.38 | Yes | -0.45 | 30.5 (GHRP-2) | Thin upper lip | NO | |
| Family F-sister (-) | p.Tyr888* | F | 8 | -1.27 | -0.86 | -0.12 | -2.68 | No | -0.56 | 65.5 (GHRP-2) | Thin upper lip | NO | |
| Family F-father (-) | p.Tyr888* | M | 42 | -1.82 | -1.93 | Thin upper lip | NO | |

*Height before rh GH treatment or recent height.
Table 3. GH treatment for heterozygous *IGF1R* mutations

| Family | Proband | Height SDS | 0 years | 1 year | 2 years | 3 years | 4 years | 5 years |
|--------|---------|-----------|---------|--------|---------|---------|---------|---------|
| B      | (p.Arg461Leu) | Height SDS | -3.43 | -2.81 | -2.34 | -2.11 | | |
|        | rhGH dose (mg·kg⁻¹·week⁻¹) | 0.25 | 0.25 | 0.25 | 0.25 | | | |
|        | Annual Δ height SDS | 0.62 | 0.47 | 0.23 | | | | |
|        | Serum IGF1 level (SDS) | -0.32 | 1.72 | 1.61 | 2.72 | | | |
| C      | (p.Asp1135Glu) | Height SDS | -3 | -2.7 | -2.37 | -2.06 | -1.89 | -2.01 |
|        | rhGH dose (mg·kg⁻¹·week⁻¹) | 0.23 | 0.35 | 0.45 | 0.45 | 0.45 | 0.45 |
|        | Annual Δ height SDS | 0.3 | 0.33 | 0.31 | 0.17 | 0 | -0.12 |
|        | Serum IGF1 level (SDS) | 3.22 | 4.36 | 5.04 | 4.36 | 4.94 | 5.59 |
| D      | (p.Gln1250*) | Height SDS | -3.09 | -2.77 | -2.53 | -2.65 | -2.46 | -2.08 |
|        | rhGH dose (mg·kg⁻¹·week⁻¹) | 0.23 | 0.23 | 0.23 | 0.2 | 0.2 | 0.2 |
|        | Annual Δ height SDS | 0.32 | 0.24 | 0 | 0.19 | 0.38 | 0 |
|        | Serum IGF1 level (SDS) | 4.77 | 8.7 | 8.75 | 6.66 | 7.46 | 6.92 |
| E      | (p.Tyr1249*) | Height SDS | -3 | -2.09 | -1.46 | -1.28 | -0.82 | -0.82 |
|        | rhGH dose (mg·kg⁻¹·week⁻¹) | 0.25 | 0.31 | 0.35 | 0.34 | 0.32 | 0.35 |
|        | Annual Δ height SDS | 0.91 | 0.63 | 0.18 | 0.46 | 0 | 0 |
|        | Serum IGF1 level (SDS) | -0.22 | 4.2 | 4.51 | 4.76 | 3.97 | 5.78 |
| F      | (p.Tyr888*) | Height SDS | -3.38 | -2.43 | | | | |
|        | rhGH dose (mg·kg⁻¹·week⁻¹) | 0.25 | 0.25 | | | | | |
|        | Annual Δ height SDS | 0.95 | | | | | |
|        | Serum IGF1 level (SDS) | -1.28 | 0.22 | | | | |
| Mean (±SD) | Height SDS | -3.18±0.19 | -2.56±0.27 | -2.18±0.42 | -2.03±0.49 | -1.72±0.68 | -1.64±0.58 |
|          | rhGH dose (mg·kg⁻¹·week⁻¹) | 0.24±0.0009 | 0.28±0.045 | 0.32±0.088 | 0.31±0.095 | 0.32±0.102 | 0.33±0.102 |
|          | Annual Δ height SDS | 0.62±0.278 | 0.42±0.148 | 0.12±0.157 | 0.21±0.165 | 0.065±0.188 |
|          | Serum IGF1 level (SDS) | 1.234±1.045 | 3.84±1.29 | 4.98±1.27 | 4.63±0.70 | 5.46±0.85 | 6.10±0.34 |